Autophagy in osteosarcoma

Advances in Experimental Medicine and Biology

Volumn 804, Issue , 2014, Pages 147-160

  O’Farrill, Janice Santiago ^a   Gordon, Nancy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autophagy; Clinical trials; Hydroxychloroquine; Osteosarcoma; Pro tumorigenic; Tumor suppressor

Indexed keywords

BECLIN 1; CANNABINOID; CISPLATIN; DOXORUBICIN; EVEROLIMUS; GEMCITABINE; HIGH MOBILITY GROUP B1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; NATURAL PRODUCT; OBATOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; RAPAMYCIN; RIDAFOROLIMUS; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; HYDROXYCHLOROQUINE;

ARTICLE; AUTOPHAGY; CARCINOGENESIS; CELL SURVIVAL; CYTOTOXICITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; HUMAN; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BONE; BONE TUMOR; DRUG EFFECT; GENETICS; LUNG; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; REVIEW; SPECIES DIFFERENCE; TUMOR CELL LINE;

MURINAE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AUTOPHAGY; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXYCHLOROQUINE; LUNG; LUNG NEOPLASMS; MICE; OSTEOSARCOMA; SPECIES SPECIFICITY;

EID: 84907168940     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-04843-7_8     Document Type: Article

References (55)

1. Gordon N, Kleinerman ES (2009) The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res 152:497-508. doi: 10.1007/978-1-4419-0284-9_29
2. Duprez L, Wirawan E, Vanden Berghe T, Vandenabeele P (2009) Major cell death pathways at a glance. Microbes Infect 11(13):1050-1062. doi: 10.1016/j.micinf.2009.08.013
3. Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23(16):2891-2906. doi: 10.1038/sj.onc.1207521
4. Shen HM, Codogno P (2011) Autophagic cell death: Loch Ness monster or endangered species? Autophagy 7(5):457-465
5. Aredia FGL, Giansanti V, Scovassi AI (2012) Autophagy and cancer. Cells 1(3):520-534
6. Sun Y, Peng ZL (2009) Programmed cell death and cancer. Postgrad Med J 85(1001):134-140. doi: 10.1136/pgmj.2008.072629
7. Yang ZJ, Chee CE, Huang S, Sinicrope FA (2011) The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10(9):1533-1541. doi: 10.1158/1535-7163.MCT-11-0047
8. Liu EY, Ryan KM (2012) Autophagy and cancer-issues we need to digest. J Cell Sci 125(Pt 10):2349-2358. doi: 10.1242/jcs.093708
9. Huber A, Rubio A, Loewith RJ (2009) Mammalian target of rapamycin signaling and cancer treatment. Cancer Chemother Rev 4(4):210-223
10. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS (2009) MTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strat 6(2):47-55, http://dx.doi.org/ 10.1016/j.ddstr.2009.12.001
11. Kang R, Zeh HJ, Lotze MT, Tang D (2011) The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 18(4):571-580. doi: 10.1038/cdd.2010.191
12. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122(6):927-939. doi: 10.1016/j.cell.2005.07.002
13. Furuya N, Yu J, Byfield M, Pattingre S, Levine B (2005) The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy 1(1):46-52
14. Ciechomska IA, Goemans GC, Skepper JN, Tolkovsky AM (2009) Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene 28(21):2128-2141. doi: 10.1038/ onc.2009.60
15. Boya P, Kroemer G (2009) Beclin 1: a BH3-only protein that fails to induce apoptosis. Oncogene 28(21):2125-2127. doi: 10.1038/onc.2009.83
16. Sun Q, Fan W, Chen K, Ding X, Chen S, Zhong Q (2008) Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 105(49):19211-19216. doi: 10.1073/pnas.0810452105
17. Lorin S, Borges A, Dos Santos LR, Souquere S, Pierron G, Ryan KM, Codogno P, Djavaheri- Mergny M (2009) c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated ewing sarcoma cells. Cancer Res 69(17):6924-6931, http://dx.doi.org/ 10.1158/0008-5472.CAN-09-1270
18. Pursiheimo JP, Rantanen K, Heikkinen PT, Johansen T, Jaakkola PM (2009) Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62. Oncogene 28(3):334-344. doi: 10.1038/ onc.2008.392
19. Noman MZ, Janji B, Berchem G, Mami-Chouaib F, Chouaib S (2012) Hypoxia-induced autophagy: a new player in cancer immunotherapy? Autophagy 8(4):704-706. doi: 10.4161/ auto.19572
20. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J (2010) The RB-E2F1 pathway regulates autophagy. Cancer Res 70(20):7882-7893. doi: 10.1158/0008-5472.can-10-1604
21. Coupienne I, Fettweis G, Piette J (2011) RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. Lasers Surg Med 43(7):557-564. doi: 10.1002/ lsm.21088
22. Huang J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D, Ni J (2012) Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 8(2):275-277. doi: 10.4161/auto.8.2.18940
23. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D (2012) HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72(1):230-238. doi: 10.1158/0008-5472. can-11-2001
24. Wong W (2013) Inhibit autophagy, STAT! Sci Signal 6(256):ec4, http://dx.doi.org/ 10.1126/ scisignal.2003913
25. Roy S, Debnath J (2010) Autophagy and tumorigenesis. Semin Immunopathol 32(4):383-396. doi: 10.1007/s00281-010-0213-0
26. Chen N, Debnath J (2010) Autophagy and tumorigenesis. FEBS Lett 584(7):1427-1435. doi: 10.1016/j.febslet.2009.12.034
27. Pardo R, Lo Re A, Archange C, Ropolo A, Papademetrio DL, Gonzalez CD, Alvarez EM, Iovanna JL, Vaccaro MI (2010) Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology 10(1):19-26. doi: 10.1159/000264680
28. Eskelinen EL (2011) The dual role of autophagy in cancer. Curr Opin Pharmacol 11(4):294-300. doi: 10.1016/j.coph.2011.03.009
29. Akin D, Law B, Progulske-fox A, Dunn WA (2009) Identification of compounds that enhance and suppress autophagy. Autophagy 5(6):910-911
30. Notte A, Leclere L, Michiels C (2011) Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 82(5):427-434. doi: 10.1016/j.bcp.2011.06.015
31. Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101(52):18030-18035. doi: 10.1073/ pnas.0408345102
32. Periyasamy-Thandavan S, Jiang M, Schoenlein P, Dong Z (2009) Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. Am J Physiol Renal Physiol 297(2):F244-F256. doi: 10.1152/ajprenal.00033.2009
33. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16(1):3-11. doi: 10.1038/ cdd.2008.150
34. Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr (2010) Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980-4990. doi: 10.1002/cncr.25426
35. Seibenhener ML, Geetha T, Wooten MW (2007) Sequestosome 1/p62-more than just a scaffold. FEBS Lett 581(2):175-179. doi: 10.1016/j.febslet.2006.12.027
36. Komatsu M, Ichimura Y (2010) Physiological significance of selective degradation of p62 by autophagy. FEBS Lett 584(7):1374-1378. doi: 10.1016/j.febslet.2010.02.017
37. Ichimura Y, Komatsu M (2010) Selective degradation of p62 by autophagy. Semin Immunopathol 32(4):431-436. doi: 10.1007/s00281-010-0220-1
38. Rebucci M, Michiels C (2013) Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85(9):1219-1226. doi: 10.1016/j.bcp.2013.02.017
39. Doroshow JH (2013) Overcoming resistance to targeted anticancer drugs. N Engl J Med 369(19):1852-1853. doi: 10.1056/NEJMe1311325
40. Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1):35-48. doi: 10.1159/000086183
41. Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47-76. doi: 10.1007/978-1-60761-416-6_4
42. Rufini A, Melino G (2011) Cell death pathology: the war against cancer. Biochem Biophys Res Commun 414(3):445-450, http://dx.doi.org/ 10.1016/j.bbrc.2011.09.110
43. Meschini S, Condello M, Marra M, Formisano G, Federici E, Arancia G (2007) Autophagymediated chemosensitizing effect of the plant alkaloid voacamine on multidrug resistant cells. Toxicol In Vitro 21(2):197-203. doi: 10.1016/j.tiv.2006.09.007
44. Meschini S, Condello M, Calcabrini A, Marra M, Formisano G, Lista P, De Milito A, Federici E, Arancia G (2008) The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. Autophagy 4(8):1020-1033
45. Dhule SS, Penfornis P, Frazier T, Walker R, Tan G, He J, John V, Pochampally R (2011) Curcumin in cyclodextrin in liposome as a delivery vehicle against osteosarcoma. Cancer Res http://dx.doi.org/10.1158/1538-7445.AM2011-4227
46. Li X, Wu WK, Sun B, Cui M, Liu S, Gao J, Lou H (2011) Dihydroptychantol A, a macrocyclic bisbibenzyl derivative, induces autophagy and following apoptosis associated with p53 pathway in human osteosarcoma U2OS cells. Toxicol Appl Pharmacol 251(2):146-154. doi: 10.1016/j.taap.2010.12.007
47. Ma D, Tremblay P, Mahngar K, Collins J, Hudlicky T, Pandey S (2011) Selective cytotoxicity against human osteosarcoma cells by a novel synthetic C-1 analogue of 7-deoxypancratistatin is potentiated by curcumin. PLoS One 6(12). http://dx.doi.org/10.1371/journal.pone.0028780
48. Bechara A, Pereira GJS, Paredes-Gamero EJ, Barbosa CMV, Nascimento FD, Hirata H, Caires ACF, Smaili SS, Bincoletto C (2011) Autophagy and apoptosis modulation in osteosarcoma cells exposed to a new palladacycle compound. Basic Clin Pharmacol Toxicol 109:59, http:// dx.doi.org/ 10.1111/j.1742-7843.2011.00722.x
49. Calvaruso G, Pellerito O, Notaro A, Giuliano M (2012) Cannabinoid-associated cell death mechanisms in tumor models (review). Int J Oncol 41(2):407-413, http://dx.doi.org/ 10.3892/ ijo.2012.1476
50. Pan J, Cheng C, Verstovsek S, Chen Q, Jin Y, Cao Q (2010) The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 293(2):167-174. doi: 10.1016/j.canlet.2010.01.006
51. Urquiza L, Zalacain M, Marrodan L, Odero MD, Lecanda F, Gomez-Manzano C, Fueyo J, Sierrasesumaga L, Patino-Garcia A, Alonso MM (2011) Enhancing autophagy as a novel approach to target osteosarcoma: combination of oncolytic adenovirus and chemotherapy. Cancer Res. http://dx.doi.org/10.1158/1538-7445.AM2011-5402
52. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68(19):7966-7974, http://dx.doi.org/ 10.1158/0008-5472. CAN-08-1333
53. Zhang Z, Shao Z, Xiong L, Che B, Deng C, Xu W (2009) Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity. J Huazhong Univ Sci Technolog Med Sci 29(6):737-740. doi: 10.1007/s11596-009-0613-3
54. Gordon N, Kleinerman ES (2010) Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 23(4):189-196. doi: 10.1089/jamp.2009.0812
55. Santiago-O'Farril (2013) in progress